Both are prohibited in sport: BPC-157 is classified under WADA category S0 as an unapproved substance banned in and out of competition
PateiroMGmezBMunekataPEBarbaFJPutnikPKovaeviDBet al
The most commonly cited red flags include: COAs from the vendor's own internal lab only, no mass spectrometry confirmation, vague or missing batch numbers, aggressive health claims on product pages, no published returns or contamination policy, and suspiciously low pricing that cannot support quality synthesis and independent testing costs
[1] [6] Additionally, it acts on appetite centres in the brain, leading to reduced food intake and, consequently, weight loss in many patients

however, it was associated with the highest rate of gastrointestinal adverse events ( A systematic review and meta-analysis conducted to investigate the efficacy of tirzepatide on glycated hemoglobin, fasting serum glucose, and body weight in patients with uncontrolled T2DM reported that tirzepatide significantly improved glycemic control and body weight with an acceptable safety profile ( The FDA has approved liraglutide (a maintenance dose of 3 mg injected daily), subcutaneous semaglutide (2.4 mg injected once weekly), and tirzepatide (515 mg injected once weekly) for chronic weight management in adults with body mass index (BMI) of 30 kg/m 2 or greater, or with a BMI of 27 kg/m 2 or greater with at least one weight-related condition (such as high BP, T2DM, or high cholesterol) to be used in addition to a reduced calorie diet and increased physical activity ( Overall, robust findings have showed that GLP-1 RAs effectively promote weight loss

Many patients begin to notice appetite changes and initial weight loss within the first few weeks of Ozempic therapy